Physician profile
Benjamin Dao
NPI 1548624059
$2,028.42
in general payments reported to CMS, 2019-2025
21 companies · $751 in 2025
The $751 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $88.39 · 2023: $602 · 2024: $587 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $528.22 | 2023-2025 | Lifevest |
| Bard Peripheral Vascular, INC. | $248.68 | 2025 | Venovo, Venclose Maven Catheter |
| E.R. Squibb & Sons, L.L.C. | $159.27 | 2024-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $159.03 | 2023-2024 | Corevalve Evolut R, Onyx Frontier, Telescope |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.07 | 2022-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $151.83 | 2024-2025 | |
| Philips North America LLC | $113.06 | 2023 | |
| Abbott Laboratories | $106.85 | 2025 | Jot Dx |
| Amgen INC. | $79.85 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $55.29 | 2024 | Xarelto |
| Novo Nordisk INC | $50.12 | 2023-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $38.26 | 2023-2024 | Verquvo |
| Irhythm Technologies, INC. | $36.21 | 2024 | Zio Monitor, Zio Xt Patch |
| Lexicon Pharmaceuticals, INC. | $30.95 | 2024 | |
| Boston Scientific Corporation | $23.77 | 2025 | Varithena Administration Pack |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Koya Medical, INC. | $20.53 | 2025 | Koya Medical, Dayspring |
| Edwards Lifesciences Corporation | $18.83 | 2024 | Sapien 3 Ultra Resilia |
| Penumbra, INC. | $18.47 | 2023 | Indigo System |
| Siemens Medical Solutions USA, INC. | $14.97 | 2025 | Cios Spin |
| Genzyme Corporation | $14.88 | 2024 | |
| Cashflow Solutions, LLC | $3.28 | 2024 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Dao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.